(Oncodesign) 新規分子放射線治療薬の開発を支援する、PSMA陽性およびFAP陽性の新規マウスモデル

要旨

• Robust preclinical models are required for the evaluation of novel PSMA-overexpressing mouse models molecular radiotherapies (MRT):
  
  • accuratelymimicking human tumor microenvironments
  • Expressing optimal levels of target proteins.

• Tow biomarkers of interest in the field of MRT and Oncology are:

1. Fibroblast activation protein (FAP): Minimally expressed in regular tissues, upregulated in cancer-associated fibroblasts within the tumor microenvironment.

2. Prostate-specific membrane antigen (PSMA): overexpressed in most prostate cancers.

• Oncodesign Services already had PSMA-overexpressing models available, but only on Balb/c Nude mice. This strain is radiosensitve due to a mutation and has become unavailable for purchase in the recent months.

• Furthermore, inherently expressing FAP models are available, but have minimal FAP-expression.

• To close the gap in our catalogue, Oncodesign Services has recently developed novel FAP and PSMA-overexpressing models in nonradiosensitve mouse strains.